Bella Vista Community Church, 75 E. Lancashire Blvd., is an evangelical interdenominational church. The Women's Bible Study classes will start a new 12-week study of "Hebrews: Christ -- Perfect ...

Thanks for clicking on the final installment of our "Fear Not" three-part mini-series. If you were busy glorifying God and missed Parts 1 and 2 about the Old Testament verses, please take a few ...

Discontinuing the use of GLP-1 weight-loss medications triggers weight regain more than previously thought, a new study suggested. The research, which was published in The BMJ, found that stopping the ...

Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within ...

-- Company to host a live webcast event with an expert panel of clinicians during ASH -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell ...

Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. PORTSMOUTH, N.H., ...

The first healthy volunteer has been dosed in a Phase 1 clinical study of CLY-124 — a novel oral small molecule that Cellarity is developing to treat sickle cell disease — following clearance of the ...

The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad ...

ACE-232 is a potent CYP11A1 inhibitor showing efficacy in preclinical models resistant to current mCRPC therapies. The phase 1 trial will enroll 67 patients to evaluate safety, tolerability, and ...

TIX100 Demonstrates Safety and Tolerability in Human Subjects, Marking a Key Drug Development Milestone Post-Hoc Analysis Reveals Promising First Biological TIX100 Signal in Humans TIXiMED to Advance ...

Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study. Phase 1b dose ...